A citation-based method for searching scientific literature

Quan Guo, Qing Yang, Jun Li, Guipeng Liu, Igor Nikoulin, Steve Jia. Anticancer Drugs 2020
Times Cited: 3







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Potential approaches for more successful dendritic cell-based immunotherapy.
Cheryl Lai-Lai Chiang, Klara Balint, George Coukos, Lana E Kandalaft. Expert Opin Biol Ther 2015
20
33

New Approaches for Immune Directed Treatment for Ovarian Cancer.
Nicola Hardwick, Paul H Frankel, Mihaela Cristea. Curr Treat Options Oncol 2016
8
33

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, Andrés M Poveda, David Cibula, Hal Hirte, Felix Hilpert, Francesco Raspagliesi, Laurence Gladieff, Philipp Harter,[...]. J Clin Oncol 2016
41
33

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
Osama E Rahma, Ed Ashtar, Malgorzata Czystowska, Marta E Szajnik, Eva Wieckowski, Sarah Bernstein, Vincent E Herrin, Mortada A Shams, Seth M Steinberg, Maria Merino,[...]. Cancer Immunol Immunother 2012
60
33

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.
Yanyu Pang, Xiaoyang Hou, Chunsheng Yang, Yanqun Liu, Guan Jiang. Mol Cancer 2018
39
33

Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Silvia Martin Lluesma, Anita Wolfer, Alexandre Harari, Lana E Kandalaft. Biomedicines 2016
35
33

Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Quan Guo, Qing Yang, Jun Li, Guipeng Liu, Igor Nikoulin, Steve Jia. Curr Pharm Biotechnol 2018
2
50

Advances in ovarian cancer therapy.
Alexander J Cortez, Patrycja Tudrej, Katarzyna A Kujawa, Katarzyna M Lisowska. Cancer Chemother Pharmacol 2018
183
33

Immunotherapy in ovarian cancer.
Venkatesh Krishnan, Jonathan S Berek, Oliver Dorigo. Curr Probl Cancer 2017
20
33

Cancer statistics, 2005.
Ahmedin Jemal, Taylor Murray, Elizabeth Ward, Alicia Samuels, Ram C Tiwari, Asma Ghafoor, Eric J Feuer, Michael J Thun. CA Cancer J Clin 2005
33

The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer.
Masanori Kobayashi, Asako Chiba, Hiromi Izawa, Eri Yanagida, Masato Okamoto, Shigetaka Shimodaira, Yoshikazu Yonemitsu, Yuta Shibamoto, Noboru Suzuki, Masaki Nagaya. J Ovarian Res 2014
24
33

Whole Tumor Antigen Vaccines: Where Are We?
Cheryl Lai-Lai Chiang, George Coukos, Lana E Kandalaft. Vaccines (Basel) 2015
120
33

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
33

Recent concepts of ovarian carcinogenesis: type I and type II.
Masafumi Koshiyama, Noriomi Matsumura, Ikuo Konishi. Biomed Res Int 2014
112
33

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
Cheryl Lai-Lai Chiang, Lana E Kandalaft, Janos Tanyi, Andrea R Hagemann, Gregory T Motz, Nikolaos Svoronos, Kathleen Montone, Gina M Mantia-Smaldone, Lori Smith, Harvey L Nisenbaum,[...]. Clin Cancer Res 2013
116
33

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Janos L Tanyi, Sara Bobisse, Eran Ophir, Sandra Tuyaerts, Annalisa Roberti, Raphael Genolet, Petra Baumgartner, Brian J Stevenson, Christian Iseli, Denarda Dangaj,[...]. Sci Transl Med 2018
171
33

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.
Lana E Kandalaft, Daniel J Powell, Cheryl L Chiang, Janos Tanyi, Sarah Kim, Marnix Bosch, Kathy Montone, Rosemarie Mick, Bruce L Levine, Drew A Torigian,[...]. Oncoimmunology 2013
103
33

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
33

Latest clinical evidence of maintenance therapy in ovarian cancer.
Christine S Walsh. Curr Opin Obstet Gynecol 2020
12
33

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial.
H J Gray, B Benigno, J Berek, J Chang, J Mason, L Mileshkin, P Mitchell, M Moradi, F O Recio, C M Michener,[...]. J Immunother Cancer 2016
18
33

Ovarian Cancer Immunotherapy: Turning up the Heat.
Eleonora Ghisoni, Martina Imbimbo, Stefan Zimmermann, Giorgio Valabrega. Int J Mol Sci 2019
57
33

Antigen-specific active immunotherapy for ovarian cancer.
Sterre T Paijens, Ninke Leffers, Toos Daemen, Wijnand Helfrich, H Marike Boezen, Ben J Cohlen, Cornelis Jm Melief, Marco de Bruyn, Hans W Nijman. Cochrane Database Syst Rev 2018
8
33


Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
William P McGuire, Richard T Penson, Martin Gore, Antonio Casado Herraez, Patrick Peterson, Ashwin Shahir, Robert Ilaria. BMC Cancer 2018
14
33

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.
Paul Lr Mitchell, Michael A Quinn, Peter T Grant, David G Allen, Thomas W Jobling, Shane C White, Anne Zhao, Vaios Karanikas, Hilary Vaughan, Geoffrey Pietersz,[...]. J Immunother Cancer 2014
21
33

Immunotherapy in Gynecologic Cancers: Are We There Yet?
Janelle B Pakish, Amir A Jazaeri. Curr Treat Options Oncol 2017
28
33

Mitochondrial protein translocases for survival and wellbeing.
Anna Magdalena Sokol, Malgorzata Eliza Sztolsztener, Michal Wasilewski, Eva Heinz, Agnieszka Chacinska. FEBS Lett 2014
65
33

Mammalian RNA switches: Molecular rheostats in gene regulation, disease, and medicine.
Kadiam C Venkata Subbaiah, Omar Hedaya, Jiangbin Wu, Feng Jiang, Peng Yao. Comput Struct Biotechnol J 2019
6
33

Neurodegeneration and RNA-binding proteins.
Laura De Conti, Marco Baralle, Emanuele Buratti. Wiley Interdiscip Rev RNA 2017
16
33

HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer.
Xiaofang Yi, Yi Zhou, Wenxin Zheng, Setsuko K Chambers. Aust N Z J Obstet Gynaecol 2009
27
33

Crosstalk between the mitochondrial fission protein, Drp1, and the cell cycle is identified across various cancer types and can impact survival of epithelial ovarian cancer patients.
Deepak Kumar Tanwar, Danitra J Parker, Priyanka Gupta, Brian Spurlock, Ronald D Alvarez, Malay Kumar Basu, Kasturi Mitra. Oncotarget 2016
42
33

HuR function in disease.
Subramanya Srikantan, Myriam Gorospe. Front Biosci (Landmark Ed) 2012
202
33

Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
Mamadou Keita, Zhi-Qiang Wang, Jean-Francois Pelletier, Magdalena Bachvarova, Marie Plante, Jean Gregoire, Marie-Claude Renaud, Anne-Marie Mes-Masson, Éric R Paquet, Dimcho Bachvarov. Gynecol Oncol 2013
42
33

RNA Binding Proteins in Intestinal Epithelial Biology and Colorectal Cancer.
Priya Chatterji, Anil K Rustgi. Trends Mol Med 2018
60
33

Adaptive and maladaptive expression of the mRNA regulatory protein HuR.
Suman Govindaraju, Beth S Lee. World J Biol Chem 2013
27
33

Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma.
Tiina-Liisa Erkinheimo, Heini Lassus, Anna Sivula, Sibani Sengupta, Henry Furneaux, Timothy Hla, Caj Haglund, Ralf Butzow, Ari Ristimäki. Cancer Res 2003
124
33

A census of human RNA-binding proteins.
Stefanie Gerstberger, Markus Hafner, Thomas Tuschl. Nat Rev Genet 2014
843
33

Epidemiology of epithelial ovarian cancer.
Penelope M Webb, Susan J Jordan. Best Pract Res Clin Obstet Gynaecol 2017
274
33

Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease.
Jinho Kim, Jennifer P Moody, Christina K Edgerly, Olivia L Bordiuk, Kerry Cormier, Karen Smith, M Flint Beal, Robert J Ferrante. Hum Mol Genet 2010
204
33


Ovarian cancer stem cells more questions than answers.
Petronella Beatrix Ottevanger. Semin Cancer Biol 2017
52
33

HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Ben Davidson, Arild Holth, Ellen Hellesylt, Rivka Hadar, Betina Katz, Claes G Tropé, Reuven Reich. Hum Pathol 2016
10
33

Functional interplay between RNA-binding protein HuR and microRNAs.
Subramanya Srikantan, Kumiko Tominaga, Myriam Gorospe. Curr Protein Pept Sci 2012
125
33

Human antigen R and drug resistance in tumors.
Fenghai Zhou, Fa Zhang, Chuan Zhou, Mengtian Liang, Zhonglin Cai, Haidi Lv, Wenjuan Li, Xupan Wei. Invest New Drugs 2019
3
33

HuR-regulated lncRNA NEAT1 stability in tumorigenesis and progression of ovarian cancer.
Yiqing Chai, Jie Liu, Zhikun Zhang, Liwei Liu. Cancer Med 2016
109
33

Translocase of inner mitochondrial membrane 44 alters the mitochondrial fusion and fission dynamics and protects from type 2 diabetes.
Yu Wang, Akihiro Katayama, Takahiro Terami, Xiaoying Han, Tomokazu Nunoue, Dongxiao Zhang, Sanae Teshigawara, Jun Eguchi, Atsuko Nakatsuka, Kazutoshi Murakami,[...]. Metabolism 2015
15
33

Multiple functions of HuR in urinary tumors.
Fa Zhang, Zhonglin Cai, Haidi Lv, Wenjuan Li, Mengtian Liang, Xupan Wei, Fenghai Zhou. J Cancer Res Clin Oncol 2019
6
33


Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
Katja Specht, Nadia Harbeck, Jan Smida, Katja Annecke, Ulrike Reich, Joerg Naehrig, Rupert Langer, Joerg Mages, Raymonde Busch, Elisabeth Kruse,[...]. Breast Cancer Res Treat 2009
27
33

Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
Carsten Denkert, Wilko Weichert, Sören Pest, Ines Koch, Dirk Licht, Martin Köbel, Angela Reles, Jalid Sehouli, Manfred Dietel, Steffen Hauptmann. Cancer Res 2004
131
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.